Acrotech Biopharma

Subsidiary of Aurobindo Pharma (AUROPHARMA)

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
Histone Deacetylase InhibitorSmall molecule
Non-Hodgkin Lymphoma
Peripheral T-Cell Lymphoma
difamilast(Moizerto / Adquey)
Approved
PDE4Small molecule
Atopic Dermatitis
Approved
DNA (guanine N7 position)Small molecule
Multiple Myeloma
Autologous Stem Cell Conditioning in Multiple Myeloma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
difamilast · Moizerto / AdqueyPhase 3Atopic Dermatitis (AD)
Est. primary completion 2026-12 · NCT07173478 · CT.gov ↗
What to watch
2027 (1)
February 2027 (1)
difamilast · Moizerto / AdqueyPhase 3Atopic Dermatitis (AD)
Est. primary completion 2027-02 · NCT07184645 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
BelinostatPhase 3Peripheral T Cell Lymphoma
Est. primary completion 2030-07 · NCT06072131 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.